Abstract
While there has been significant progress in the treatments for lung cancer over the past decade, it remains the leading cause of cancer death as of 2019. The discovery of the epidermal growth factor receptor (EGFR) mutation in lung cancer cells has led to treatments with EGFR inhibitors which have yielded results superior to chemotherapy in patients who harbor this mutation. Toxicities with EGFR inhibitors are very different than standard chemotherapy but can be managed with the proper evaluation and treatment.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Cancer facts & figures 2019. American Cancer Society Web site. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2019/cancer-facts-and-figures-2019.pdf. Accessed 29 Jan 2019.
Melosky B. Supportive care treatments for toxicities of anti-EGFR and other targeted agents. Curr Oncol. 2012;19(Suppl 1):S59–63. https://doi.org/10.3747/co.19.1054.
Harari PM. Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer. 2004;11(4):689–708.
Tsao AS, Tang XM, Sabloff B, et al. Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer. J Thorac Oncol. 2006;1:231–9.
NCCN clinical practice guidelines in oncology: non-small cell lung cancer. Version 2.2019. National comprehensive Cancer Network Web site. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Published 21 Nov 2018. Accessed 15 Jan 2019.
Kuan F-C, Kuo L-T, Chen M-C, et al. Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysis. Br J Cancer. 2015;113:1519–28.
Mok TS, Wu Y-L, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:10.
Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239–46.
Yang JC-H, Sequist LV, Geater SL, et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-lung 2, LUX-lung 3, and LUX-lung 6. Lancet Oncol. 2015;16:830–8.
Sequist LV, Yang JC-H, Yamamoto N, et al. LUX-Lung 3: phase III study of afatinib or cisplatin plus pemetrexed in patients EGFR mutations. J Clin Oncol. 2013;31:3327–34.
Soria J-C, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378(2):113–25.
Wu YL, Cheng Y, Zhou X, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHEL 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(11):1454–66.
Fabbrocini G, Panariello L, Caro G, Cacciapuoti S. Acneiform rash induced by EGFR inhibitors: review of the literature and new insights. Skin Appendage Disord. 2015;1:21–37.
United States, Department of Health and Human Services, National Institutes of Health, National Cancer Institute (NCI). Common Terminology Criteria for Adverse Events (CTCAE). Ver. 4.03. Bethesda, MD. 2010. Available online at: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf; cited 29 Apr 2012.
Hirsh V. Managing treatment-related adverse events associated with EGFR tyrosine kinase inhibitors in advanced non-small- cell lung cancer. Curr Oncol. 2011;18:126–38.
Lacouture ME, Anadkat MJ, Bensadoun R-J, Bryce J, Chan A, Epstein JB, Eaby-Sandy B, Murphy BA. Clinical practice guidelines for the prevention and treatment of EGFR-associated dermatologic toxicities. Support Care Cancer. 2011;19:1079–95.
Lynch TJ, Kim ES, Eaby B, et al. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist. 2007;12:610–21.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Turner, M.M., Eaby-Sandy, B. (2019). Nursing Considerations with EGFR Inhibitors in NSCLC. In: Davies, M., Eaby-Sandy, B. (eds) Targeted Therapies in Lung Cancer: Management Strategies for Nurses and Practitioners. Springer, Cham. https://doi.org/10.1007/978-3-030-16550-5_3
Download citation
DOI: https://doi.org/10.1007/978-3-030-16550-5_3
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-16549-9
Online ISBN: 978-3-030-16550-5
eBook Packages: MedicineMedicine (R0)